Oncolytic Herpes Viral Therapy is Effective in the Treatment of Hepatocellular Carcinoma Cell Lines

Taejin Song, David P. Eisenberg, Prasad S. Adusumilli, Michael Hezel, Yuman Fong

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The rising incidence of hepatocellular carcinoma (HCC) in western countries, along with the poor prognosis offered by present-day treatment modalities, makes novel therapies for this disease necessary. Oncolytic herpes simplex viruses (HSV) are replication-competent viruses that are highly effective in the treatment of a wide variety of experimental models of human malignancies. This study seeks to investigate the effectiveness of oncolytic herpes viruses in the treatment of primary HCC cell lines. Sixteen commercially available human HCC cell lines were studied. G207 is an attenuated, replication-competent, oncolytic HSV engineered to selectively replicate within cancer cells. Cell lines were tested for viral sensitivity to G207 and their ability to support viral replication using standard cytotoxicity and viral replication assays. Eleven of 16 cell lines were moderately to highly sensitive to G207 viral oncolysis. HCC cell lines additionally demonstrated the ability to support viral replication in vitro with as high as 800-fold amplification of the administered viral dose observed. G207 is cytotoxic to, and efficiently replicates within, HCC cell lines in vitro. From these data, we suggest that oncolytic HSV therapy may have a role in the treatment of HCC, and in vivo studies are warranted.

Original languageEnglish
Pages (from-to)532-542
Number of pages11
JournalJournal of Gastrointestinal Surgery
Volume10
Issue number4
DOIs
Publication statusPublished - 2006 Apr 1
Externally publishedYes

Fingerprint

Oncolytic Viruses
Hepatocellular Carcinoma
Cell Line
Simplexvirus
Therapeutics
Virus Replication
Neoplasms
Theoretical Models
Viruses
Incidence
In Vitro Techniques

Keywords

  • G207
  • gene therapy
  • hepatocellular carcinoma
  • herpes simplex virus

ASJC Scopus subject areas

  • Surgery

Cite this

Oncolytic Herpes Viral Therapy is Effective in the Treatment of Hepatocellular Carcinoma Cell Lines. / Song, Taejin; Eisenberg, David P.; Adusumilli, Prasad S.; Hezel, Michael; Fong, Yuman.

In: Journal of Gastrointestinal Surgery, Vol. 10, No. 4, 01.04.2006, p. 532-542.

Research output: Contribution to journalArticle

Song, Taejin ; Eisenberg, David P. ; Adusumilli, Prasad S. ; Hezel, Michael ; Fong, Yuman. / Oncolytic Herpes Viral Therapy is Effective in the Treatment of Hepatocellular Carcinoma Cell Lines. In: Journal of Gastrointestinal Surgery. 2006 ; Vol. 10, No. 4. pp. 532-542.
@article{b437af30ef384741965b97198ef3c441,
title = "Oncolytic Herpes Viral Therapy is Effective in the Treatment of Hepatocellular Carcinoma Cell Lines",
abstract = "The rising incidence of hepatocellular carcinoma (HCC) in western countries, along with the poor prognosis offered by present-day treatment modalities, makes novel therapies for this disease necessary. Oncolytic herpes simplex viruses (HSV) are replication-competent viruses that are highly effective in the treatment of a wide variety of experimental models of human malignancies. This study seeks to investigate the effectiveness of oncolytic herpes viruses in the treatment of primary HCC cell lines. Sixteen commercially available human HCC cell lines were studied. G207 is an attenuated, replication-competent, oncolytic HSV engineered to selectively replicate within cancer cells. Cell lines were tested for viral sensitivity to G207 and their ability to support viral replication using standard cytotoxicity and viral replication assays. Eleven of 16 cell lines were moderately to highly sensitive to G207 viral oncolysis. HCC cell lines additionally demonstrated the ability to support viral replication in vitro with as high as 800-fold amplification of the administered viral dose observed. G207 is cytotoxic to, and efficiently replicates within, HCC cell lines in vitro. From these data, we suggest that oncolytic HSV therapy may have a role in the treatment of HCC, and in vivo studies are warranted.",
keywords = "G207, gene therapy, hepatocellular carcinoma, herpes simplex virus",
author = "Taejin Song and Eisenberg, {David P.} and Adusumilli, {Prasad S.} and Michael Hezel and Yuman Fong",
year = "2006",
month = "4",
day = "1",
doi = "10.1016/j.gassur.2005.08.036",
language = "English",
volume = "10",
pages = "532--542",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Oncolytic Herpes Viral Therapy is Effective in the Treatment of Hepatocellular Carcinoma Cell Lines

AU - Song, Taejin

AU - Eisenberg, David P.

AU - Adusumilli, Prasad S.

AU - Hezel, Michael

AU - Fong, Yuman

PY - 2006/4/1

Y1 - 2006/4/1

N2 - The rising incidence of hepatocellular carcinoma (HCC) in western countries, along with the poor prognosis offered by present-day treatment modalities, makes novel therapies for this disease necessary. Oncolytic herpes simplex viruses (HSV) are replication-competent viruses that are highly effective in the treatment of a wide variety of experimental models of human malignancies. This study seeks to investigate the effectiveness of oncolytic herpes viruses in the treatment of primary HCC cell lines. Sixteen commercially available human HCC cell lines were studied. G207 is an attenuated, replication-competent, oncolytic HSV engineered to selectively replicate within cancer cells. Cell lines were tested for viral sensitivity to G207 and their ability to support viral replication using standard cytotoxicity and viral replication assays. Eleven of 16 cell lines were moderately to highly sensitive to G207 viral oncolysis. HCC cell lines additionally demonstrated the ability to support viral replication in vitro with as high as 800-fold amplification of the administered viral dose observed. G207 is cytotoxic to, and efficiently replicates within, HCC cell lines in vitro. From these data, we suggest that oncolytic HSV therapy may have a role in the treatment of HCC, and in vivo studies are warranted.

AB - The rising incidence of hepatocellular carcinoma (HCC) in western countries, along with the poor prognosis offered by present-day treatment modalities, makes novel therapies for this disease necessary. Oncolytic herpes simplex viruses (HSV) are replication-competent viruses that are highly effective in the treatment of a wide variety of experimental models of human malignancies. This study seeks to investigate the effectiveness of oncolytic herpes viruses in the treatment of primary HCC cell lines. Sixteen commercially available human HCC cell lines were studied. G207 is an attenuated, replication-competent, oncolytic HSV engineered to selectively replicate within cancer cells. Cell lines were tested for viral sensitivity to G207 and their ability to support viral replication using standard cytotoxicity and viral replication assays. Eleven of 16 cell lines were moderately to highly sensitive to G207 viral oncolysis. HCC cell lines additionally demonstrated the ability to support viral replication in vitro with as high as 800-fold amplification of the administered viral dose observed. G207 is cytotoxic to, and efficiently replicates within, HCC cell lines in vitro. From these data, we suggest that oncolytic HSV therapy may have a role in the treatment of HCC, and in vivo studies are warranted.

KW - G207

KW - gene therapy

KW - hepatocellular carcinoma

KW - herpes simplex virus

UR - http://www.scopus.com/inward/record.url?scp=33646040377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646040377&partnerID=8YFLogxK

U2 - 10.1016/j.gassur.2005.08.036

DO - 10.1016/j.gassur.2005.08.036

M3 - Article

VL - 10

SP - 532

EP - 542

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 4

ER -